| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
REVIEW |
Correspondence to:
Correspondence to:
K Rockwood
Centre for Health Care of the Elderly, 5955 Veterans’ Memorial Lane, Suite 1421, Halifax, Nova Scotia, Canada B3H 2E1; kenneth.rockwood{at}dal.ca
Background: Six cholinesterase inhibitors (ChEIs) have been tested in people with Alzheimer’s disease, using methods currently required for regulatory approval. The clinical importance of their treatment effects is controversial.
Objective: To determine whether cholinesterase inhibition produces treatment effects in Alzheimer’s disease that are large enough to be clinically detectable.
Methods: Overview analysis of published trials of ChEIs in which the Alzheimer’s Disease Assessment Scale—Cognitive Subscale (ADAS-Cog) and a global clinical measure were primary outcomes. Two quantitative summary measures of the treatment effect (Cohen’s d and the standardised response mean (SRM)) were calculated and presented as funnel plots. Observed cases analyses and intention to treat (ITT) with the last observation carried forward (LOCF) analyses were compared.
Results: The median Cohen’s d effect sizes (ES) using ITT samples with LOCF for the ADAS-Cog were: low dose of a ChEI (n = 8 studies) median ES = 0.15, range = 0.03–0.22; medium dose (n = 13) median ES = 0.23, range = 0.12–0.29; high dose (n = 9) median ES = 0.28, range = 0.01–0.31. In general, the ES were larger when calculated as SRMs (for example, high dose ChEI studies, median SRM = 0.47; range = 0.30–0.63) and highest in the observed cases analyses (for example, high dose median SRM = 0.56, range = 0.35–0.78).
Global clinical scales produced similar estimates of ES (for example, high dose ChEI, ITT/LOCF median Cohen’s d = 0.29, range = 0.20–0.47).
Conclusions: ChEIs produce small-moderate effect sizes in clinical trials which are reproducible and demonstrate a dose response. Better descriptions of the patterns of treatment response are needed to guide individual patient decisions about the effectiveness of treatment, but group effects are evident and appear large enough to be clinically detectable.
Keywords: Alzheimer’s disease; systematic review; cholinesterase inhibitors
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale—Cognitive Subscale; ChEIs, cholinesterase inhibitors; CIBIC-Plus, Clinician’s Interview-Based Impression of Change Plus Caregiver Input; ITT, intention to treat; LOCF, last observation carried forward; OC, observed cases; SRM, standardised response mean
This article has been cited by other articles:
|
|
 |
|
  K. Rockwood, S. Fay, P. Jarrett, and E. Asp Effect of galantamine on verbal repetition in AD: A secondary analysis of the VISTA trial Neurology, April 3, 2007; 68(14): 1116 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Paskavitz, J. J. Gunstad, and J. E. Samuel Clock Drawing and Frontal Lobe Behavioral Effects of Memantine in Alzheimer's Disease: A Rater-Blinded Study American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 454 - 459. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Rockwood, S. Fay, X. Song, C. MacKnight, M. Gorman, and on behalf of the Video-Imaging Synthesis of Treati Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial Can. Med. Assoc. J., April 11, 2006; 174(8): 1099 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Jelic, M Kivipelto, and B Winblad Clinical trials in mild cognitive impairment: lessons for the future J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 429 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Becker Treating Alzheimer's disease: Do clinical trial methods produce unnecessary practitioner dilemmas? American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 81 - 84. [Abstract] [PDF]
|
|
|
|
|
|
K Herholz Action of cholinesterase inhibitors in patients' brains J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 305 - 305. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Ment. Health, November 1, 2004; 7(4): 100 - 100. [Full Text] [PDF]
|
|
|
|
 |
|
 23 Apr 2004 to 23 Jul 2004 Evid. Based Nurs., October 1, 2004; 7(4): e4 - e4. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., September 1, 2004; 9(5): e5 - e5. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
